CVS Caremark Advances Biosimilar Adoption to Expand Patient Access and Reduce Specialty Medication Costs
CVS Caremark is strengthening its commitment to improving healthcare affordability and expanding access to essential medications through the increased adoption of biosimilars. As healthcare organizations, employers, and health plans continue looking for ways to control rising prescription drug expenses, biosimilars are emerging as an important option for making advanced treatments more accessible while maintaining established standards of safety, quality, and effectiveness.
The growing availability of biosimilars is creating new opportunities across the U.S. healthcare system. By introducing additional competition into the biologic medication market, these treatments can help reduce prescription drug costs, provide patients with more affordable treatment options, and support employers and health plans in managing healthcare spending.
CVS Caremark, the pharmacy benefit management business of CVS Health, is expanding its biosimilar strategy across several therapeutic areas. The company’s efforts include changes to its commercial formularies, increased preference for lower-cost alternatives, and initiatives designed to encourage broader adoption of FDA-approved biosimilar medications.
Recent findings from a survey conducted by CVS Caremark and Employee Benefit News (EBN) highlight the increasing interest among employers in biosimilars as part of their pharmacy benefit strategies. The research indicates that organizations are recognizing the potential of these medications to address specialty drug expenses while maintaining patient access to clinically appropriate treatments.
The survey found that nearly half of employers questioned currently encourage biosimilar coverage. Another 40% are actively considering or exploring biosimilar adoption as part of their pharmacy benefit strategies.
These findings demonstrate growing interest in alternative approaches to managing prescription drug costs, particularly as specialty medications account for an increasingly important share of healthcare spending.
CVS Caremark-EBN Study Highlights Growing Employer Interest in Biosimilars
The survey conducted by CVS Caremark and Employee Benefit News provides insight into how employers view biosimilars and their potential role in improving healthcare affordability.
Employers are increasingly evaluating pharmacy benefit strategies that can help balance medication access, treatment quality, and financial sustainability.
According to the survey, nearly 50% of participating employers said they currently encourage coverage of biosimilars. An additional 40% reported that they are considering or exploring the approach.
These findings suggest that biosimilars are becoming a more prominent consideration in employer-sponsored healthcare plans.
For employers, prescription drug spending represents an important component of overall healthcare costs. Specialty medications can create particularly significant financial challenges because many are used to treat complex, chronic, or rare medical conditions and may involve substantial treatment expenses.
Biosimilars provide an opportunity to introduce competition into markets traditionally dominated by expensive biologic medications.
As additional biosimilar products become available, employers and health plans can evaluate whether these alternatives may help reduce costs while maintaining access to appropriate therapies.
The survey also highlighted the importance of specialty medication access when employers select pharmacy benefit management partners.
Approximately 43% of surveyed employers identified specialty drug access as a top consideration when choosing a pharmacy benefit manager (PBM).
This finding reflects the growing expectation that PBM organizations should provide solutions that address both medication affordability and access to specialty treatments.
For CVS Caremark, the results reinforce the importance of its ongoing efforts to expand biosimilar adoption and provide clients with additional opportunities to manage prescription drug expenses.
Understanding Biosimilars and Their Role in Modern Healthcare
Biosimilars are FDA-approved biological products that are highly similar to an already approved reference biologic medicine.
They have no clinically meaningful differences from their reference products in terms of safety, purity, and potency.
Unlike conventional generic medications, which generally contain chemically identical active ingredients to their reference drugs, biosimilars are developed from complex biological materials and require specialized manufacturing processes.
Biologic medicines have transformed treatment for numerous serious and chronic conditions. They are used across several medical specialties, including oncology, immunology, rheumatology, gastroenterology, and endocrinology.
These medications have helped expand treatment options for patients with conditions that may require advanced therapeutic approaches.
However, biologic medicines can also represent a substantial portion of prescription drug spending.
Biosimilars offer an additional option by introducing competition into the market for these treatments.
When multiple products become available for a particular biologic therapy, healthcare organizations and pharmacy benefit managers can evaluate pricing, coverage arrangements, and product availability to identify opportunities for savings.
For patients, increased competition may improve access to treatments that might otherwise create financial challenges.
For employers and health plans, biosimilars can provide another approach to managing prescription drug budgets without requiring a move away from established biologic treatment options.
The growing adoption of these medications is therefore becoming an important part of discussions about the future of specialty pharmacy and healthcare affordability.
CVS Caremark’s Strategy to Accelerate Biosimilar Adoption
CVS Caremark has taken several steps to encourage the use of biosimilars across its pharmacy benefit management business.
One of the company’s major initiatives began in 2024, when CVS Caremark became the first pharmacy benefit manager to remove Humira® from its major national commercial template formularies in favor of biosimilar alternatives.
Humira, a biologic medication widely used to treat several inflammatory and autoimmune conditions, has historically represented an important area of specialty prescription drug spending.
The introduction of biosimilar alternatives created additional competition and provided healthcare organizations with opportunities to consider lower-cost treatment options.
CVS Caremark’s formulary changes were designed to accelerate the adoption of these alternatives by encouraging coverage of biosimilar products rather than continuing to prioritize the reference biologic.
The strategy represented a significant development in the company’s approach to specialty medication affordability.
According to CVS Caremark, its biosimilar initiatives have helped clients and members achieve approximately $3.3 billion in gross savings while maintaining access to treatment.
These savings demonstrate the potential financial impact of biosimilar adoption when pharmacy benefit strategies are designed to encourage competition and the use of lower-cost alternatives.
The company continues to expand its approach into additional therapeutic categories, reflecting its broader objective of making specialty medications more affordable.
Expanding Biosimilar Coverage Across Multiple Therapeutic Areas
CVS Caremark’s biosimilar strategy is not limited to one medication or therapeutic category.
The company has expanded adoption into several areas, including osteoporosis, multiple sclerosis, and rare blood disorders.
These therapeutic categories involve patients who may require ongoing medication management and long-term treatment.
In osteoporosis care, biologic treatment options can play an important role for certain patients at increased risk of fractures. The availability of biosimilar alternatives may provide additional opportunities for managing medication costs.
In multiple sclerosis, treatment strategies may involve specialized therapies designed to manage the disease and reduce its impact on patients. Expanding access to lower-cost alternatives can be relevant when evaluating treatment affordability.
Rare blood disorders represent another area where biologic medications can be important components of patient care. Access to appropriate treatments is particularly significant for individuals managing uncommon medical conditions that may require specialized therapies.
By extending biosimilar adoption across these therapeutic areas, CVS Caremark is working to provide clients with additional options for managing specialty pharmacy spending.
The approach also reflects the increasing availability of biosimilars across different segments of the pharmaceutical market.
As more products receive regulatory approval and enter commercial distribution, pharmacy benefit managers have additional opportunities to evaluate formulary arrangements and encourage competition.
However, medication selection and coverage decisions must continue to account for individual patient needs, clinical appropriateness, and applicable prescribing requirements.
CVS Caremark Updates Formularies to Prefer Stelara Biosimilars
Another important development in CVS Caremark’s biosimilar strategy involves its commercial formulary changes related to Stelara®.
The company recently updated key commercial formularies to prefer lower-cost interchangeable biosimilars over Stelara.
Stelara is a biologic medication used in the treatment of certain immune-mediated inflammatory conditions.
The availability of biosimilar alternatives creates additional competition in this therapeutic category and provides pharmacy benefit managers with opportunities to develop coverage strategies focused on affordability.
CVS Caremark’s formulary changes are intended to encourage the use of lower-cost interchangeable biosimilar products while maintaining access to clinically appropriate care.
The company expects that most affected members will have no out-of-pocket costs for their therapy under the updated approach.
This aspect of the initiative is particularly important because prescription drug expenses can create financial difficulties for patients requiring long-term specialty medications.
Even when treatments are covered by insurance, deductibles, copayments, and coinsurance can affect what patients ultimately pay.
By prioritizing lower-cost alternatives and structuring coverage to support affordability, CVS Caremark aims to reduce financial barriers for eligible members.
The Stelara-related formulary updates also demonstrate how biosimilar competition can influence pharmacy benefit management strategies beyond the company’s earlier initiatives involving Humira.
Improving Access to Specialty Medications While Managing Costs
Specialty medications remain an important area of focus for healthcare organizations because of their clinical complexity and financial impact.
These medications are frequently used to treat serious, chronic, or uncommon diseases and may require specialized dispensing, monitoring, and patient support services.
As demand for advanced therapies increases, employers and health plans face the challenge of maintaining access while controlling the financial impact of prescription drug spending.
The CVS Caremark-EBN study highlights this issue by showing that specialty medication access is a major consideration for employers evaluating PBM partnerships.
The finding that 43% of surveyed employers consider specialty drug access a top factor when selecting a PBM partner reflects the importance of affordability and treatment availability in pharmacy benefit management.
Biosimilars can help address this challenge by introducing additional treatment options that may be available at lower costs than their reference biologics.
However, successful adoption requires more than simply adding alternative medications to a formulary.
Pharmacy benefit managers must also consider coverage policies, physician communication, patient education, product availability, and the clinical circumstances of individual patients.
CVS Caremark’s strategy combines formulary changes with broader efforts to encourage biosimilar adoption across different therapeutic categories.
The company aims to use competition among biologic medicines and biosimilars to create opportunities for savings while supporting access to appropriate treatments.
How Biosimilars Can Benefit Employers, Health Plans, and Patients
The growing adoption of biosimilars has implications for several stakeholders across the healthcare system.
For patients: Biosimilars may provide access to lower-cost alternatives to established biologic medications. Depending on insurance coverage and benefit design, these alternatives may help reduce financial barriers to treatment.
For employers: Biosimilars offer an additional tool for managing pharmacy benefit expenses, particularly in specialty medication categories where biologic therapies can represent substantial costs.
For health plans: Increased competition can provide more flexibility when developing formularies and designing prescription drug coverage strategies.
For healthcare providers: A broader range of approved treatment options can support discussions about appropriate medication choices, provided decisions remain consistent with individual clinical needs.
For pharmacy benefit managers: Biosimilars create opportunities to develop strategies that balance medication affordability, access, and clinically appropriate treatment.
The financial benefits of biosimilars can vary depending on product pricing, market competition, reimbursement arrangements, and individual insurance benefit designs.
Nevertheless, their growing availability is creating additional opportunities to address prescription drug affordability.
Competition Is Reshaping the Specialty Pharmaceutical Market
The introduction of biosimilars is changing the competitive environment for biologic medications.
Historically, certain biologic products have operated in markets with limited direct competition. The development and approval of biosimilars have created additional options for healthcare organizations and pharmacy benefit managers.
This increased competition can influence product pricing, formulary decisions, and commercial strategies across the pharmaceutical industry.
For pharmaceutical manufacturers, biosimilar competition creates new market dynamics that may require changes to pricing and commercialization approaches.
For employers and health plans, the availability of additional products can create opportunities to evaluate alternatives and negotiate more favorable coverage arrangements.
For patients, broader competition may improve the affordability of important treatments.
CVS Caremark’s initiatives involving Humira and Stelara demonstrate how formulary strategies can help accelerate biosimilar adoption.
The company’s reported $3.3 billion in gross savings for clients and members further highlights the potential financial impact of its approach.
As the biosimilar market continues to develop, the ability to incorporate these medications into pharmacy benefit strategies may become increasingly important for organizations seeking to manage specialty drug expenses.
Moving Toward a More Affordable Healthcare System
The CVS Caremark-EBN study highlights growing employer recognition of biosimilars as a potential solution to healthcare affordability challenges.
With nearly half of surveyed employers already encouraging biosimilar coverage and another 40% considering the approach, interest in these medications is continuing to expand.
CVS Caremark is building on this momentum through its formulary initiatives, expansion into additional therapeutic areas, and preference for lower-cost interchangeable biosimilars.
The company’s efforts are focused on creating opportunities for patients to access established biologic treatments through more affordable alternatives while helping employers and health plans manage specialty medication expenses.
The reported $3.3 billion in gross savings associated with its biosimilar strategy represents a significant financial outcome highlighted by the company.
At the same time, the continued expansion of biosimilar coverage into osteoporosis, multiple sclerosis, rare blood disorders, and other therapeutic areas demonstrates the broader potential of these products.
As more biosimilars enter the market, competition is expected to remain an important factor in shaping specialty pharmacy coverage and prescription drug affordability.
Ultimately, CVS Caremark’s biosimilar initiatives reflect a broader healthcare industry effort to balance three important priorities: affordable medications, accessible treatment options, and high standards of clinical care.
By continuing to expand biosimilar adoption and encourage competition, CVS Caremark aims to support a more sustainable pharmacy benefit environment while helping patients obtain the medications they need.
Source link: https://www.cvshealth.com/
